Mayne Pharma: Eryc™ / Erymax™ Capsules

By: Mayne Pharma (cda)  09-12-2011
Keywords: health care, Benefits Scheme, Pharmaceutical Benefits Scheme,

Eryc™ capsules are a delayed release erythromycin (a macrolide antibiotic) produced by Mayne Pharma using proprietary pellet technology.

Indicated for the treatment of a wide variety of bacterial infections, Eryc™ erythromycin is formulated to protect erythromycin degrading in the acidic environment of the stomach, for optimal absorption in the intestine.

Eryc™ capsules are available in two dose strengths, 250mg and 333mg.

Eryc™ erythromycin capsules are currently licensed and sold in Australia, Canada, Sweden and the United Kingdom. Opportunities remain for licensing in a significant number of international territories.

Mayne Pharma offers Eryc™ capsules on the Pharmaceutical Benefits Scheme (PBS) in Australia.

This product is prescription only. Your doctor will advise you whether this product is suitable for you. Always read the label. Use only as directed. If symptoms persist see your health care professional.

Further Information

Keywords: Benefits Scheme, health care, Pharmaceutical Benefits Scheme,

Contact Mayne Pharma (cda)


Print this page

Other products and services from Mayne Pharma (cda)


Mayne Pharma: Astrix™ Capsules & Tablets

Astrix™ aspirin tablets are an immediate release low-dose form of aspirin indicated for inhibition of platelet aggregation to help prevent heart attack and stroke in patients with known cardiovascular and cerebrovascular disease. Your doctor will advise you whether using Astrix™ capsules or tablets as part of an overall program to manage the risk of heart attack or stroke is suitable for you.


Mayne Pharma: Doryx™ Capsules & Tablets

Doryx™ capsules and tablets are delayed release oral formulations of doxycycline, that can be used treat certain types of infections, as adjunctive treatment of severe acne and as an anti-malarial. Doryx™ capsules and tablets contains enteric-coated pellets of doxycycline hyclate and is the only delayed release pelletised doxycycline product on the market.